Trials / Completed
CompletedNCT04347915
The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19
A Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Bukwang Pharmaceutical · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 120 mg versus placebo once daily administration with standard of care therapy for 14 days (maximum up to 21 days) in patients with moderate COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clevudine | Clevudine 120mg once a day for 14 days (up to 21 days) |
| DRUG | Placebo | Matching Placebo once a day for 14 days (up to 21 days) |
Timeline
- Start date
- 2020-05-26
- Primary completion
- 2021-02-24
- Completion
- 2021-02-26
- First posted
- 2020-04-15
- Last updated
- 2022-07-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04347915. Inclusion in this directory is not an endorsement.